Diabetes, Vol 37, Issue 11 1574-1582, Copyright © 1988 by American Diabetes Association

ARTICLES

Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group

A randomized double-blind placebo-controlled trial was undertaken to determine whether cyclosporin enhances remission of insulin-dependent diabetes mellitus (IDDM) through the 1st yr after diagnosis. Dosage with insulin was minimized with target control of blood glucose levels less than or equal to 7.8 mM (140 mg/dl) before meals. Metabolic control was evaluated by serial determinations of glycosylated hemoglobin levels, and endogenous secretion of insulin was evaluated by determination of the levels of glucagon-stimulated insulin-connecting peptide (CP) in the plasma at 3-mo intervals. A compound definition of remission required a glucagon-stimulated CP level in plasma greater than or equal to 0.6 nM or a non-insulin-receiving state (NIR) in which target control of glycemia was maintained without administration of insulin. A clinical definition of remission required only the NIR state as defined. One hundred eighty-eight patients aged 10-35 yr entered the study within 6 wk of initiation of insulin therapy and within 14 wk of onset of symptoms and were studied for 1 yr. There were no significant differences in metabolic control between the two treatment groups during the study. The anticipated adverse effects of cyclosporin were not more frequent or severe than in other experience with the drug, but histological changes attributable to cyclosporin were present in some kidney biopsies obtained from selected patients after 1 yr. At 1 yr, by the compound definition, 33% of the cyclosporin-group and 21% of the placebo-group patients were in remission, when the corresponding rates for NIR remissions were 24 and 10%.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. C. Voltarelli, C. E. B. Couri, A. B. P. L. Stracieri, M. C. Oliveira, D. A. Moraes, F. Pieroni, M. Coutinho, K. C. R. Malmegrim, M. C. Foss-Freitas, B. P. Simoes, et al. Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in Newly Diagnosed Type 1 Diabetes Mellitus JAMA, April 11, 2007; 297(14): 1568 - 1576. [Abstract] [Full Text] [PDF]

				K. M. Gillespie Type 1 diabetes: pathogenesis and prevention. Can. Med. Assoc. J., July 18, 2006; 175(2): 165 - 170. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Insulin Treatment and Type 1 Diabetes Topics Diabetes Care, April 1, 2006; 29(4): 936 - 944. [Full Text] [PDF]

				P. Narendran, E. Estella, and S. Fourlanos Immunology of type 1 diabetes QJM, August 1, 2005; 98(8): 547 - 556. [Full Text] [PDF]

				B. Keymeulen, E. Vandemeulebroucke, A. G. Ziegler, C. Mathieu, L. Kaufman, G. Hale, F. Gorus, M. Goldman, M. Walter, S. Candon, et al. Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes N. Engl. J. Med., June 23, 2005; 352(25): 2598 - 2608. [Abstract] [Full Text] [PDF]

				A. Lernmark Type 1 Diabetes -- Does Suppressing T Cells Increase Insulin? N. Engl. J. Med., June 23, 2005; 352(25): 2642 - 2644. [Full Text] [PDF]

				Z. T. Bloomgarden Diabetes Issues in Women and Children: Polycystic ovary syndrome Diabetes Care, August 1, 2003; 26(8): 2457 - 2463. [Full Text] [PDF]

				C. J. Greenbaum and L. C. Harrison Guidelines for Intervention Trials in Subjects With Newly Diagnosed Type 1 Diabetes Diabetes, May 1, 2003; 52(5): 1059 - 1065. [Full Text] [PDF]

				S. A. Brod Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity Experimental Biology and Medicine, December 1, 2002; 227(11): 981 - 988. [Abstract] [Full Text]

				M. R. Christie, J. Molvig, C. J. Hawkes, B. Carstensen, T. Mandrup-Poulsen, and the Canadian-European Randomised Control Trial Gro IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin Diabetes Care, July 1, 2002; 25(7): 1192 - 1197. [Abstract] [Full Text] [PDF]

				E. A.M. Gale Can We Change the Course of Beta-Cell Destruction in Type 1 Diabetes? N. Engl. J. Med., May 30, 2002; 346(22): 1740 - 1742. [Full Text] [PDF]

				D. M. Nathan The Impact of Clinical Trials on the Treatment of Diabetes Mellitus J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 1929 - 1937. [Abstract] [Full Text] [PDF]

				L. Bertry-Coussot, B. Lucas, C. Danel, L. Halbwachs-Mecarelli, J.-F. Bach, L. Chatenoud, and P. Lemarchand Long-Term Reversal of Established Autoimmunity upon Transient Blockade of the LFA-1/Intercellular Adhesion Molecule-1 Pathway J. Immunol., April 1, 2002; 168(7): 3641 - 3648. [Abstract] [Full Text] [PDF]

				M. Dufer, P. Krippeit-Drews, N. Lembert, L.-A. Idahl, and G. Drews Diabetogenic Effect of Cyclosporin A Is Mediated by Interference with Mitochondrial Function of Pancreatic B-Cells Mol. Pharmacol., October 1, 2001; 60(4): 873 - 879. [Abstract] [Full Text] [PDF]